간염 진단 및 치료 시장 예측(2025-2030년)

The Hepatitis Diagnostic And Treatment Market is expected to grow from USD 33.224 billion in 2025 to USD 39.915 billion in 2030, at a CAGR of 3.74%.

The global hepatitis diagnostic and treatment market is experiencing significant growth, driven by the rising prevalence of hepatitis infections, particularly hepatitis B and C, which account for the majority of hepatitis-related mortality. Hepatitis, characterized by liver inflammation, is caused by viruses A, B, C, D, E, and G, with B and C being the most prevalent due to their chronic nature. Key factors fueling market expansion include increasing alcohol and drug consumption, improved access to hepatitis medications, and ongoing advancements in diagnostic and treatment methodologies. The market is poised for robust growth through 2030, supported by global efforts to enhance hepatitis care delivery.

Market Segmentation Analysis

By Type

The market is segmented into diagnostics and treatment. Diagnostic methods include blood tests, DNA and RNA testing, liver biopsies, and ultrasounds, which are critical for early detection and disease management. Treatments range from antiviral medications and injectable alpha interferons for chronic hepatitis B and C to liver transplants in severe cases. The diagnostic segment is growing due to the need for precise and accessible testing, while advancements in antiviral therapies drive the treatment segment.

By Disease Type

The market is categorized into Hepatitis A, B, C, and others (D, E, G). Hepatitis B and C dominate due to their high global prevalence and chronic impact, particularly in regions with limited healthcare access. Hepatitis A, while significant, is less chronic and often preventable, whereas B and C require long-term management, fueling demand for advanced treatments.

By Geography

North America holds a significant market share, attributed to its advanced healthcare infrastructure, widespread access to novel medications, and growing public awareness of hepatitis. The Asia-Pacific region is expected to witness rapid growth, driven by a high burden of hepatitis B and C, particularly in endemic areas like China and eastern Asia, alongside improving healthcare access. Europe, the Middle East, Africa, and South America also contribute, with regional efforts to address varying disease prevalence and treatment needs.

Competitive Landscape

The hepatitis diagnostic and treatment market is highly competitive, featuring major global players such as Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc. These companies are focusing on expanding their geographic reach and innovating new treatments, such as next-generation antivirals and diagnostic tools, to strengthen their market positions. Strategic collaborations and R&D investments are key to addressing unmet needs and regulatory requirements.

Market Outlook

The hepatitis diagnostic and treatment market is set for substantial growth through 2030, driven by rising disease prevalence, improved drug access, and treatment innovations. North America's dominance and Asia-Pacific's rapid expansion highlight significant opportunities, while challenges like high treatment costs are being addressed through global health initiatives. The market's trajectory underscores its critical role in combating chronic viral hepatitis worldwide.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

The hepatitis diagnostic and treatment market has been analyzed through the following segments:

By Type

• Blood Test
• DNA Test
• Liver Biopsy
• RNA Testing
• Liver Ultrasound
• Treatment
• Drugs
• Injectable alpha Interferons
• Liver Transplant

By Disease Type

• Hepatitis A
• Hepatitis B
• Hepatitis C
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

• 5.1. Introduction
• 5.2. Blood Test
• 5.3. DNA Test
• 5.4. Liver Biopsy
• 5.5. RNA Testing
• 5.6. Liver Ultrasound

6. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TREATMENT

• 6.1. Introduction
• 6.2. Drugs
• 6.3. Injectable alpha Interferons
• 6.4. Liver Transplant

7. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY DISEASE TYPE

• 7.1. Introduction
• 7.2. Hepatitis A
• 7.3. Hepatitis B
• 7.4. Hepatitis C
• 7.5. Others

8. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Siemens AG
• 10.2. F.Hoffmann La-Roche
• 10.3. Abbott Laboratories
• 10.4. DiaSorin S.p.A
• 10.5. bioMeriuex
• 10.6. MedMira, Inc.
• 10.7. Bio-Rad Laboratories

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations